Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Annovis Bio, Inc.

35 indications, side-by-side phase, drug & LoA

$1.78

-0.05 (-2.7%)

D 35Pipeline Score Overvalued Pharma · Commercial
Market Cap
64.44 M
EPS
-1.72
P/E Ratio
-1.08 $
Value Trade
1.27 M
SEC Financials
Q1 2026

  • Dilution Risk

    80%

  • Revenue

    -

  • R&D Expenses

    16.72 M

  • Operating CF

    -9.01 M

  • Total Assets

    16.24 M

  • Total Liabilities

    13.12 M

  • Equity

    3.13 M

  • D/E Ratio

    12,345

9.85 %
Week
17.99 %
1 Month
-5.51 %
3 Month
-42.97 %
6 Month
-96.58 %
5 Year
-66.37 %
All Time
Cash Data
Distressed

  • Cash Position

    14.22 M

  • Monthly Burn

    3.00 M

  • Runway

    3.8 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 15, 2026
Overview
Volume
628.75 K
52 Week Range
1.54 - 5.50
% held by Insiders
13.66 %
% held by Institutions
16.52 %
Enterprise Value
50.22 M
Total Shares
26.51 M
Short %
16.79 %
Float Shares
22.24 M
Company Description
HQ: 101 LINDENWOOD DRIVE, SUITE 22...
Founded:2008
Employees:7
https://www.annovisbio.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 3 data readout example
buntanetap Alzheimer's disease (AD)
Phase 3
—
Small Molecules
Nervous System
buntanetap Alzheimer's disease (AD)
Phase 3
—
Small Molecules
Nervous System
buntanetap Alzheimer's disease (AD)
Phase 3
—
Small Molecules
Nervous System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D35
Pipeline Score
$37M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.6x
rNPV / MCap
Top 43%
Micro Cap
(rank 517 of 905)
Percentile Rank
Annovis Bio, Inc. faces pipeline headwinds (35/100), with $926M risk-adjusted pipeline value, led by buntanetap/posiphen in Early Alzheimers Disease (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
buntanetap/posiphen
Small molecule		Early Alzheimers DiseasePhase 3NCT0670901448% $788M ACTIVE NOT_RECRUITING 760 FAST A (84) Jun 1, 2028LOW_RISKMEDIUM
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
buntanetap
Alzheimer's disease,Parkinson's disease
Phase 3
2025-08-08
buntanetap
Alzheimer's disease,Parkinson's disease
Phase 3
2025-08-08
buntanetap
Alzheimer's disease,Parkinson's disease
Phase 3
2025-08-08
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ANVS
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ANVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ANVS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ANVS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-260 0.00 0 0 - - - - - -
2026-06-260 0.00 0 0 - - - - - -
2026-06-260 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Annovis Bio, Inc. (ANVS) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ANVS ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Neuromodulation Techniques #1 of 1 PHASE 2 buntanetap/posiphen
—
—0.9 LEADER
Alzheimer's Disease #4 of 24 PHASE 3 buntanetap/posiphen
BMY LLY BIIB
$6.49B 0.95 CONTENDER
Parkinson's Disease #9 of 22 PHASE 2 buntanetap/posiphen
SUPN PRTA BHVN
$5.96B 0.9 FOLLOWER